ANAPTYSBIO, INC
For the period ended Mar 31, 2026. Filed May 12, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 12, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
Rule 10b5-1 Trading Arrangements
As disclosed below, during the three months ended March 31, 2026, certain of our directors or officers adopted, modified orterminated any “Rule 10b5-1 trading arrangements” or any “non-Rule 10b5-1 trading arrangements,” as each term is defined in Item 408 of Regulation S-K.
On January 13, 2026, Dennis Mulroy, ourformer chief financial officer, entered into a written plan for the potential sale of common stock. The plan was subsequently terminated on March 25, 2026.
On January 14, 2026, Paul Lizzul, ourformer chief medical officer, entered into a written plan for the potential sale of common stock. The plan was subsequently terminated on March 3, 2026. On March 3, 2026, Dr. Lizzul, also terminated a written 10b5-1 Plan dated April 14, 2025.
On March 3, 2026, Eric Loumeau, ourformer chief legal officer, terminated a written 10b5-1 Plan dated April 11, 2025.
On March 30, 2026, Hollings Renton, one of ourdirectors, entered into a written plan for the potential sale of up to an aggregate 15,000 shares of common stock. The plan is intended to satisfy the affirmative defense condition of Rule 10b5-1(c) under the Exchange Act and is scheduled to terminate no later than February 24, 2027.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.